MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs
The collaboration provides external validation of MultiOmic Health’s AI-enabled precision medicine discovery platform and innovative renal therapeutic programs
MultiOmic Health announces discovery of novel endotypes and biomarkers for diabetic kidney disease
MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.
MultiOmic Health and Queen’s University Belfast join forces to transform diabetic kidney disease diagnosis
MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, is embarking on a collaborative project with the Centre for Public Health at Queen’s University Belfast (QUB) in Northern Ireland to develop data-driven diagnostic tools for Diabetic Kidney Disease (DKD).
MultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related Conditions
MultiOmic Health has closed a £5 million seed extension round to build its precision therapeutics discovery platform for metabolic syndrome.
MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease
MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease
MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease
MultiOmic Health and Mesh Bio announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease.